2. 职称英语
  3. The Roslin Institute announced last week that it had applied to patent the me

The Roslin Institute announced last week that it had applied to patent the me

游客2023-12-18  17
问题    The Roslin Institute announced last week that it had applied to patent the method by which its scientists had cloned Dolly the sheep. The patent, if granted, would apply to "nuclear transfer technology" in both human and animal cells. One point of the patent is to help fund research into cures for diseases such as Parkinson’s, Alzheimer’s, cancer and heart failure.
   Its other aim is to make some money. Last May, the Roslin Institute was taken over by Geron, an American biotech company. Geron has committed ＄32.5 million to research at the Roslin. It wants to get its money back. Two scientists from Stanford who developed the use of restriction enzymes, one of the fundamental techniques in biotechnology, made about pounds 80 million out of it in the 17 years before the patent expired. So you can see why Geron-Roslin is so keen to get its patent. There’s nothing wrong with that. Without the prospect of a return at the end of investment, no one would ever lend money to anyone involved in bio-medical research—and given the huge sums now required to develop a new drug, or a new diagnostic test for some medical condition, that would mean there wouldn’t be any research. It is wonderful when people give money to worthwhile causes with no hope of personal gain. But appealing to altruism simply won’t raise the billions required to develop and market drugs and therapies that rely on biotechnology. For that, you have to appeal to investors’ self-interest—which is why the bulk of medical research is funded not by charities or even tax-payers but by private companies and individuals.
   The fact that biotech research depends on patents generates profound hostility. The opposition to the patenting of genetic sequences, cells, tissues and clones—critics call it "the privatization of nature"—takes many forms, from a Luddite desire to stop scientific research to a genuine, if mistaken, conviction that common ownership is always morally preferable to private property. But all of the objections have a single root. the sense that it must be wrong to make money out of the constituents of the human body. They cannot be "owned" by any individual, because they belong to everyone. There cannot be "property in people".
   That is a profound mistake. The truth is rather the opposite: there is only property in things because there is property in people. People own their own bodies, and that ownership is the basis of their property rights (and most other individual rights, come to that). The problem with the law as it stands is that it doesn’t sufficiently recognize an individual’s property rights over his or her own body, and his or her entitlement to make money out of it.
   The outcome of a lawsuit in the US nearly 10 years ago defined the de facto rules governing the ownership of human tissues, and the financial exploitation of the discoveries that derive from them. In Moorev the Regents of UCLA the issue was whether an individual was entitled to a share of the profits that a biotech company made from developing drugs or treatments derived from cells that came from his body. Dr David Golde had discovered that John Moore, one of his patients, had a pancreas whose cells had some unusual properties that might be helpful in treating a form of cancer. In his laboratory, Golde developed what his called a "cell line" from Moore’s cells and patented it. When Moore found out, he sued Dr Golde for a share of whatever profits the cell line generated.
   Mr. Moore lost. The court said he had no right to any of those profits, because he did not own the cells removed from his body. Moreover, the court held that since "research on human cells plays a critical role in medical research", granting property rights to the patient from whom the cells came threatened to "hinder research by restricting access to the raw materials".
   In essence, that decision said that biotech companies could own and make money out of human cells and tissue—but the person from whom that tissue or cells came could not. The logic behind that decision is bizarre. No one except the most unreconstructed communist disputes that I own my own body. Indeed, it is only because I own my body that I can come to own anything else independent of it, mixing my labor with something being the most fundamental means by which I can come to own it. If cells from Mr. Moore’s body are his property, how can anyone else come to own them—unless he sells or gives those cells to them? (778 words) [br] What does the author argue about in this passage?
选项 A、There is only the property in things because there is property in people. People own their bodies and that ownership is the basis of their property.
B、Common ownership is always morally preferable to private property. The patenting of genetic sequences, tissues and clones is "the privatization of nature".
C、Whether an individual was entitled to a share of the profits that a biotech company made from developing drug or treatments derived from cells that came from his body.
D、A biotech company might spend a lot of money on enhancing their value, which might give them a claim to a large share of profits.
答案 A
解析 作者在文章中间才亮出自己的观点，即只有在事物本身上才有所有权，因为人本身有所有权。人拥有他自己的身体，而这种所有关系是他们所有权这个权利的基础所在。第二项是与作者论点相左的，即公共所有在道德上总是比私人所有更恰当。对于器官组织和克隆的专利就是“人性的私有”。第三项援引了默尔的例子来阐释作者的立场。这个例子的关键点是个人的身体器官被生物公司用于研制药物或治疗方法后，此人是否理应得到该生物公司的一部分利润。第四项是生物公司也许会出一部分钱用于提高他们(默尔)的价值也许会使他们要求获得更多的利润，但这并不消除器官所有者对该器官的最初的所有权，这是针对默尔案例的分析，故也排除了。
转载请注明原文地址:https://tihaiku.com/zcyy/3282943.html
相关试题推荐
随机试题
最新回复(0)